Dr. Kishor M. Bhende
Claim this profileCovenant Children's Hospital
About Kishor M. Bhende
Education:
- Earned an MD from Grant Medical College, India, in 1998.
- Completed a Residency in Pediatrics at Cohen Children's Medical Center, Zucker School of Medicine at Hofstra/Northwell (2011-2013).
- Undertook a Fellowship in Pediatric Hematology/Oncology at Louisiana State University School of Medicine (2008-2011).
Experience:
- Boasts over 11 years of experience in Pediatrics and Pediatric Hematology-Oncology.
- Board-certified in Pediatrics and Pediatric Hematology-Oncology.
- Practices at Covenant Children's Hospital and SWCC at University Medical Center in Lubbock, TX.
- Serves as an Assistant Professor of Pediatrics at Texas Tech University Health Sciences Center.
Area of expertise
Cancer
Kishor M. Bhende has run 11 trials for Cancer. Some of their research focus areas include:
Neuroblastoma
Kishor M. Bhende has run 11 trials for Neuroblastoma. Some of their research focus areas include:
Affiliated Hospitals
Covenant Children's Hospital
Clinical Trials Kishor M. Bhende is currently running
Selumetinib vs. Chemotherapy
for Brain Cancer
This trial is comparing a new drug, selumetinib, with standard chemotherapy to treat patients with a specific type of brain tumor. The patients do not have a certain genetic mutation and are not affected by a genetic disorder. Selumetinib works by blocking enzymes needed for tumor growth, while the standard drugs kill or stop tumor cells from dividing.
Recruiting
2 awards
Phase 3
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting
2 awards
Phase 3
More about Kishor M. Bhende
Clinical Trial Related
8 years of experience running clinical trials · Led 36 trials as a Principal Investigator · 13 Active Clinical Trials
Treatments Kishor M. Bhende has experience with
- Cyclophosphamide
- Etoposide
- Doxorubicin Hydrochloride
- Vincristine Sulfate
- Radiation Therapy
- Methotrexate
Breakdown of trials Kishor M. Bhende has run
Cancer
Neuroblastoma
Rhabdomyosarcoma
Brain Tumor
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Kishor M. Bhende specialize in?
Kishor M. Bhende focuses on Cancer and Neuroblastoma. In particular, much of their work with Cancer has involved Stage I patients, or patients who are Stage IV.
Is Kishor M. Bhende currently recruiting for clinical trials?
Yes, Kishor M. Bhende is currently recruiting for 13 clinical trials in Lubbock Texas. If you're interested in participating, you should apply.
Are there any treatments that Kishor M. Bhende has studied deeply?
Yes, Kishor M. Bhende has studied treatments such as Cyclophosphamide, Etoposide, Doxorubicin Hydrochloride.
What is the best way to schedule an appointment with Kishor M. Bhende?
Apply for one of the trials that Kishor M. Bhende is conducting.
What is the office address of Kishor M. Bhende?
The office of Kishor M. Bhende is located at: Covenant Children's Hospital, Lubbock, Texas 79410 United States. This is the address for their practice at the Covenant Children's Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.